Breaking Canadian GLP-1 news
GLP-1 News — Page 7
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Canadians Battle Insurers for Semaglutide Coverage Amid Generic Delay
CTV News reports Canadians are still fighting insurers to cover Ozempic as generic semaglutide remains unapproved more than three months after patent expiry.
Apotex Has Three Separate Generic Semaglutide Filings in Canada
Apotex has filed three separate generic semaglutide applications with Health Canada in January, April and November 2025, the Globe and Mail reports.
Oldest Generic Semaglutide Filing Dates to February 2024
Health Canada's generic semaglutide queue includes applications filed as early as February 2024, with nine submissions pending and Apotex holding three 2025 filings.
Sandoz Eyes End-of-June Canadian Launch for Unbranded Semaglutide
Sandoz told Reuters unbranded Ozempic could launch in Canada by end of June, as generic semaglutide rolls out across India, China, Brazil and Turkey.
Canadian Patients, Doctors Frustrated by Generic Semaglutide Delay
Over three months after Canada's semaglutide patent expired, none of the nine generic applications at Health Canada have been approved, frustrating patients.
Apotex Wins US Tentative Nod for Generic Semaglutide, Canada Waits
Apotex secured tentative FDA approval for generic semaglutide developed with Orbicular, while three of its Canadian applications remain under Health Canada review.
Health Canada Reviewing GLP-1 Aspiration Pneumonia Anesthesia Risk
Health Canada opened a safety review of GLP-1 receptor agonists for aspiration pneumonia risk during general anesthesia or deep sedation, records show.
Alberta Blue Cross Flags MASH, Sleep Apnea as Next GLP-1 Uses
Alberta Blue Cross's 2026 pipeline report says GLP-1 uses may expand to MASH and obstructive sleep apnea, keeping plan spend high despite mid-2026 generics.
Lilly Sets $50 US Medicare Price for Zepbound as Canada Awaits
Eli Lilly announces $50 monthly Medicare pricing for Zepbound in US starting April 2026, while Canadian patients await Health Canada decisions on coverage.
Apotex Wins Tentative FDA Approval for Generic Ozempic
Canadian generic manufacturer Apotex receives tentative FDA approval for generic semaglutide while Health Canada reviews nine generic applications.
pCPA Sets Tiered Pricing Framework for Generic Semaglutide
Pan-Canadian Pharmaceutical Alliance establishes structured pricing tiers for generic semaglutide medications entering Canadian market mid-2026.
Ozempic Drives 8.5% of Canada's Public Drug Cost Growth
New data shows Ozempic has become Canada's largest publicly funded single-drug cost driver, representing 8.5% of total public drug spending growth.
Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada grants new indication for Rybelsus oral semaglutide tablet to reduce cardiovascular risks in adults with Type 2 diabetes and heart disease.
South African Aspen Pharmacare Targets Canada Entry Q3 2026
South African pharmaceutical giant Aspen Pharmacare aims to launch generic semaglutide in Canada by third quarter 2026 as reference market for emerging regions.
Novo Nordisk Cuts Wegovy to $149 Monthly Ahead of Generics
Novo Nordisk launches $149 monthly Wegovy pricing through August 2026 as company prepares for generic semaglutide competition in Canadian market.
Canadian Pharmacies Report GLP-1 Prices Range $300-570 Monthly
Current pharmacy pricing data shows Ozempic and Wegovy costs vary significantly across Canadian provinces, with monthly supplies ranging from $300 to $570 CAD.
Dr. Reddy's Generic Semaglutide Under Health Canada Review Since 2024
India-based pharmaceutical company Dr. Reddy's Laboratories submitted generic semaglutide application to Health Canada in early 2024, currently under review.
Canadian Semaglutide Sales Hit $3.5 Billion in 2025
IQVIA Canada reports total semaglutide sales including Ozempic and Wegovy reached $3.5 billion in 2025, highlighting market size before generic competition.
CMA Advises Patients Generic GLP-1s Coming Mid-2026
Canadian Medical Association tells patients generic GLP-1 medications expected around mid-2026, not immediately after patent expiry in January.
Health Canada Adds Submission Class Data to Drug Review Tracker
Health Canada's drug review tracker now shows submission class information as of March 20, 2026, providing more transparency for generic approvals.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada